BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27277477)

  • 1. Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway.
    Cornu JN; Audet-Walsh E; Drouin S; Bigot P; Valeri A; Fournier G; Azzouzi AR; Roupret M; Cormier L; Chanock S; Guillemette C; Cussenot O; Lévesque E; Cancel-Tassin G
    World J Urol; 2017 Feb; 35(2):293-298. PubMed ID: 27277477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway.
    Lévesque E; Laverdière I; Audet-Walsh E; Caron P; Rouleau M; Fradet Y; Lacombe L; Guillemette C
    Clin Cancer Res; 2014 Jun; 20(11):2971-83. PubMed ID: 24682418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy.
    Audet-Walsh É; Bellemare J; Lacombe L; Fradet Y; Fradet V; Douville P; Guillemette C; Lévesque É
    Eur Urol; 2012 Jul; 62(1):88-96. PubMed ID: 22209174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The androgen receptor CAG repeat length polymorphism associates with prostate volume in Finnish men with benign prostatic hyperplasia.
    Renko O; Savolainen ER; Loikkanen I; Paavonen TK; Vaarala MH
    DNA Cell Biol; 2008 Feb; 27(2):109-13. PubMed ID: 17979523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutathione S-transferase gene variants and risk of benign prostate hyperplasia in a North Indian population.
    Konwar R; Manchanda PK; Chaudhary P; Nayak VL; Singh V; Bid HK
    Asian Pac J Cancer Prev; 2010; 11(2):365-70. PubMed ID: 20843117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
    Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
    Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy.
    Huang SP; Huang LC; Ting WC; Chen LM; Chang TY; Lu TL; Lan YH; Liu CC; Yang WH; Lee HZ; Hsieh CJ; Bao BY
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3068-74. PubMed ID: 19900942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitric oxide synthase 2 gene polymorphisms are associated with prostatic volume in Korean men with benign prostatic hyperplasia.
    Yoo KH; Kim SK; Chung JH; Chang SG
    Asian J Androl; 2010 Sep; 12(5):690-6. PubMed ID: 20562898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms in genes involved in sex hormone metabolism may increase risk of benign prostatic hyperplasia.
    Roberts RO; Bergstralh EJ; Farmer SA; Jacobson DJ; Hebbring SJ; Cunningham JM; Thibodeau SN; Lieber MM; Jacobsen SJ
    Prostate; 2006 Mar; 66(4):392-404. PubMed ID: 16302261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Determinants of Metabolism and Benign Prostate Enlargement: Associations with Prostate Volume.
    Giri A; Edwards TL; Motley SS; Byerly SH; Fowke JH
    PLoS One; 2015; 10(7):e0132028. PubMed ID: 26158673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of fibroblast growth factor receptor genes in benign prostate hyperplasia in a Korean population.
    Park HJ; Kim SK; Kim JW; Lee SH; Yoo KH; Chung JH
    Dis Markers; 2013; 35(6):869-75. PubMed ID: 24385678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness.
    Robles-Fernandez I; Martinez-Gonzalez LJ; Pascual-Geler M; Cozar JM; Puche-Sanz I; Serrano MJ; Lorente JA; Alvarez-Cubero MJ
    PLoS One; 2017; 12(10):e0185447. PubMed ID: 28981526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Relation between benign prostatic hyperplasia and obesity and estrogen].
    Matsuda T; Abe H; Suda K
    Rinsho Byori; 2004 Apr; 52(4):291-4. PubMed ID: 15164594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression.
    Lévesque É; Huang SP; Audet-Walsh É; Lacombe L; Bao BY; Fradet Y; Laverdière I; Rouleau M; Huang CY; Yu CC; Caron P; Guillemette C
    Clin Cancer Res; 2013 Feb; 19(3):699-709. PubMed ID: 23186779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic variants in the Hippo pathway predict biochemical recurrence after radical prostatectomy for localized prostate cancer.
    Huang CY; Huang SP; Lin VC; Yu CC; Chang TY; Juang SH; Bao BY
    Sci Rep; 2015 Feb; 5():8556. PubMed ID: 25707771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recovery of urinary continence following radical prostatectomy: the impact of prostate volume--analysis of data from the CaPSURE Database.
    Konety BR; Sadetsky N; Carroll PR;
    J Urol; 2007 Apr; 177(4):1423-5; discussion 1425-6. PubMed ID: 17382745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mid term outcomes of initial 250 case experience with GreenLight 120W-HPS photoselective vaporization prostatectomy for benign prostatic hyperplasia: comparison of prostate volumes < 60 cc, 60 cc-100 cc and > 100 cc.
    Hueber PA; Ben-Zvi T; Liberman D; Bhojani N; Gautam G; Deklaj T; Katz M; Zorn KC
    Can J Urol; 2012 Oct; 19(5):6450-8. PubMed ID: 23040627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between the prostatic tissue components and natural history of benign prostatic hyperplasia.
    Matsuda T; Fujime M; Suda K
    Anal Quant Cytol Histol; 2006 Jun; 28(3):121-4. PubMed ID: 16786720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.